EBITDAR for the quarter was $264 million, a 16.2% decline. EBITDAR margin stood at 33.6%, down 5.1 percentage points. As of September 30, 2025, cash, cash equivalents and short-term investments were ...
Novartis to buy Avidity, and ...
TMX Group Limited (TSX: X) (“TMX Group”) announced results for the third quarter ended September 30, 2025. Commenting on the first nine months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback